Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Alumis Inc. Common StockNASDAQ: ALMS
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow growth accelerates
Q2 FY2026 financing cash flow of $12.63M rose 1586.0% year over year, ahead of the +53.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 96.4% from the prior quarter. Over 3 fiscal years it compounded at -72.7% a year.
Context
- Financing cash flow amounted to 8.6% of revenue in FY2025.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1586.0% holds above the trailing-twelve-month pace of +53.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 2.07M USD
- Year-over-year change
- -99.6%
- 3-year CAGR
- -72.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.07M | -99.6% |
| FY2024 | 2024-12-31 | 492.37M | +449.0% |
| FY2023 | 2023-12-31 | 89.68M | -11.8% |
| FY2022 | 2022-12-31 | 101.63M | — |
Financing Cash Flow vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +53.0% is the 2nd highest of 9, against a peer median of -76.3%.
- Financing cash flow amounts to 4878.8% of revenue for ALMS, versus a peer median of 623.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M USD | +53.0% | -72.7% | 4878.8% |
| LTM Mar 2026 | $102.81M USD | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $52.19M USD | -29.8% | — | 623.8% | |
| LTM Mar 2026 | $15.99M USD | -76.2% | — | 27094.9% | |
| LTM Mar 2026 | $10.8M USD | +25.0% | -54.9% | 3.6% | |
| FY2025 | $10.01M USD | +178.0% | — | — | |
| LTM Mar 2026 | €6.23M EUR | -77.3% | +154.7% | 21245.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $342K USD | -100.2% | — | — |
| LTM Mar 2026 | $191.89K USD | -76.4% | -2.7% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -76.3% | -2.7% | 623.8% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| Deferred Income Tax | 0 | 0 | 0 | (8.56M) |
| Stock-Based Compensation | 5.96M | 8.63M | 19.46M | 43.52M |
| Change in Working Capital | (1.92M) | 12.06M | 14.76M | 26.32M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.29M | (642K) | 8.51M | (6.04M) |
| Other Working Capital | (3.21M) | 12.7M | 6.25M | 32.35M |
| Other Non-Cash Items | (86K) | 3.05M | 1.79M | (190.98M) |
| Operating Cash Flow | (107.72M) | (129.98M) | (255.08M) | (369.52M) |
| Capital Expenditures | (2.41M) | (4.5M) | (1.73M) | (653K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (209.08M) | (11.28M) | (240.06M) | (209.17M) |
| Sales of Investments | 142.73M | 76.25M | 128M | 447.96M |
| Other Investing Activities | 0 | 0 | 0 | 49.74M |
| Investing Cash Flow | (68.75M) | 60.47M | (113.79M) | 287.88M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 193.32M | 2.08M |
| Common Stock Repurchased | 0 | 0 | 0 | (17K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.73M | (96K) | 40.59M | 0 |
| Financing Cash Flow | 101.63M | 89.68M | 492.37M | 2.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (74.85M) | 20.18M | 123.5M | (79.58M) |
| Free Cash Flow | (110.13M) | (134.47M) | (256.81M) | (370.18M) |
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.